Metabolic syndrome and its related biochemical derangements in breast cancer patients who received neoadjuvant chemotherapy: A study from a tertiary care oncology centre from Puducherry, South India. Issue 3 (May 2021)

• Record Type: Journal Article
• Authors: Gomes, Slanda Litty; Bobby, Zachariah; Ganesan, Prasanth; Saroja, Kovvuri; Parameswari G, Renuka
• Is Part Of: Diabetes & metabolic syndrome. Volume 15:Issue 3(2021)
• Page Start: 975
• Page End: 980
• Publication Date: 2021-05
• Subjects: Metabolic syndrome -- Triple negative breast cancer -- Type 2 diabetes mellitus; Diabetes -- Periodicals; Metabolism -- Disorders -- Periodicals; Diabetes Mellitus -- Periodicals; Metabolic Diseases -- Periodicals; Diabète -- Périodiques; Métabolisme, Troubles du -- Périodiques; Endocrinologie -- Périodiques; Diabète -- Physiopathologie -- Périodiques; Diabetes; Metabolism -- Disorders; Electronic journals; Periodicals; 616.462
• DOI: 10.1016/j.dsx.2021.04.022
• Languages: English
• ISSNs: 1871-4021

Abstract

Abstract: Background and aims: Comparison of the existence of metabolic syndrome, its components and their related biochemical complications between newly diagnosed and treated breast cancer patients. Methods: Forty newly diagnosed untreated breast cancer patients and forty breast cancer patients who had received 7 cycles of neoadjuvant chemotherapy were recruited as group 1 and group 2 respectively. Height, weight, blood pressure, hormonal status, and tumor size were noted. The fasting blood glucose and lipid profile were estimated in AU 5811 Beckman coulter Clinical chemistry analyzer. Fasting insulin was estimated using Beckman Coulter access immunoassay system (UnicelDxI600). HbA1c assay was carried out in HPLC based ion exchange chromatography (Tosoh automated glycohemoglobin analyzer G8. Homeostasis Model Assessment 2-IR (HOMA 2-IR), HOMA-% B and HOMA-% S were calculated using an online calculator HOMA CALCULATOR [Oxford University]. Serum hsCRP and MDA were estimated by ELISA. FRAP assay was carried out manually to measure antioxidant status. Results: The existence of metabolic syndrome as well as type 2 diabetes was higher in the treated group when compared to the untreated patients. However, there were no significant differences in the indices of glucose homeostasis, low grade inflammation, oxidative stress and individual components of metabolic syndrome between the two groups. The triple negative patients were more prone to develop metabolic syndrome when compared to the triple positive patients. Conclusion: Suitable therapeutic approaches may be planned out to address the metabolic syndrome and its related complications among breast cancer patients especially during the course of treatment. Highlights: The existence of Diabetes and Metabolic syndrome was higher among the treated compared to untreated breast cancer patients. There were no differences in the existence of individual components and their related derangements between two groups. The triple negative patients were more prone to develop metabolic syndrome when compared to the triple positive patients. Medical oncologists may address development of metabolic syndrome during chemotherapy by suitable therapeutic approaches.